| Theme | Gastrointestinal Lymphoma -- Recent Advances in the Diagnosis and Management | |
|---|---|---|
| Title | Management of Gastrointestinal Follicular Lymphoma | |
| Publish Date | 2012/12 | |
| Author | Hiroyuki Okada | Department of Endoscopy, Okayama University Hospital |
| Author | Katsuyoshi Takata | Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science |
| Author | Tadashi Yoshino | Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science |
| Author | Katsushi Shinagawa | Department of Haematology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science |
| Author | Kazuhide Yamamoto | Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science |
| [ Summary ] | Management of gastrointestinal (GI) follicular lymphoma (FL) is performed based on treatments employed for nodal FL. Due to the slow course of this condition watch and wait is an acceptable option, especially for some asymptomatic patients with localized FL. Immunotherapy, using rituximab with or without the CHOP regimen delivers high treatment efficacy and has been adopted for symptomatic patients with advanced stage FL. Irrespective of high frequency of reccurence after remission, second line treatments are also very effective. Therefore, good prognoses may be expected. In a multicenter, retrospective study including 125 patients with stage I and II1 GI-FL in Japan, during a median follow up of 40 months, no patient died of FL and the over all survival and progression free survival rates after 5 years were 100 % and 93 %, respectively. | |